Heron Therapeutics Inc vs The Coca-Cola Co K — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while The Coca-Cola Co K trades at $86.62 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 5894.3× Heron Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | KO | |
|---|---|---|
Market Cap | $63.41M | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $89.08 |
52-Week Low | $0.33 | $65.67 |
Enterprise Value | $161.31M | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →